Search

Renal apseler çocukluk yaş grubunda nadir görülürler. Tanıda gecikmeler böbrek kaybına neden olabilir. Tedavi yöntemi de halen tartışmalıdır. Ek hastalığı olmayan geniş spektrumlu antibiyoterapi ile regrese olmayan , organize oldugu için perkütan drenajla drene olmadığı için opere ettiğimiz büyük renal apseli hasta literatür eşliğinde değerlendirildi., Renal abscesses are rarely seen in the childhood period. Delays in diagnosis may cause kidney loss. The treatment method is still controversial. The patient with a large renal abscess, which we operated on because it did not regress with broad-spectrum antibiotic therapy and was not drained with percutaneous drainage because it was organized, was evaluated in the light of the literature.

GİRİŞ ve AMAÇ: Büyüme hormonu (BH)tedavisi, erken epifiz kapanmasına neden olan kemik matürasyonundaki ilerlemekonusunda artan endişelerle, kemik matürasyonuna uyarıcı etkide bulunabilir. Buçalışmada, bu olasılığın araştırılması ve ilerlemiş kemik matürasyonununtahmini veya son boya etkisinin olup olmadığının saptanmasını amaçladık. YÖNTEM ve GEREÇLER: 1995-2005 tarihleri arasında BH tedavisi alan toplam 230hastanın verileri retrospektif olarak değerlendirildi. Hastalar; izole BHeksikliği (Grup 1), Turner sendromu (Grup 2) ve diğer (Grup 3) olarak ayrıldı.Önceki el bileği X-ray verileri tıbbi kayıtlardan çıkarıldı ve klinikvizitlerde el bilek X-ray istendi. Kemik yaşı (KY) değerlendirilmesi Greulichve Pyle atlasına göre yapıldı. Tahmini yetişkin boyu, KY kullanılarak Bayley vePinneau metoduna göre yapıldı. Bazal tahmini boy ile tedavinin 1. ve 2.yılındaki tahmini boy, takvim yaş (TY)-KY ve TY/KY değişkenlikleri kullanılarakdeğerlendirildi.BULGULAR: Her üç grupta boy SDS anlamlı olarak arttı (p

Giriş: Bu çalışmada, hastanemizde büyüme hormonu BH eksikliği tanısıyla izlenençocuklarda tedaviye yanıtı belirleyen etkenlerin belirlenmesi amaçlanmıştır. Gereç ve Yöntem: İzole idyopatik BH eksikliği nedeniyle takip edilen ve BH tedavisikullanan toplam 149 hastanın verileri retrospektif olarak incelendi. Bulgular: Tanı aşamasında bakılan ortalama maksimum BH yanıtı klonidin stimülasyontesti için 4,58 ng/ml, glukagon stimülasyon testi için ise 6,01 ng/ml bulundu. OrtalamaBH dozu 0,215 0,18-0,25 mg/kg/hafta olarak belirlendi. BH tedavisi ile boy SDS anlamlıolarak arttı p< 0,05 . Klonidin ve glukagon uyarısına maksimum BH yanıtı ile boyuzaması arasındaki ilişki negatif yönde anlamlı bulundu p< 0,05 . Uyarı testlerineverilen maksimum yanıta göre hastalar 7 ng/ml olarak ayrıldığında,tedaviye en yüksek yanıtın hem klonidin ve hem de glukagon testlerinde 0,05 . Sonuç: Tedaviye erken başlanan, uyarı testlerinde daha düşük BH yanıtı veren ve dahayüksek doz BH verilen hastaların tedaviden daha çok yarar gördüğü saptandı. Bunedenle, BH eksikliği tanı kriterlerinin gözden geçirilmesi gerektiği, uyarı testlerindekabul edilen 10 ng/ml sınırının aşırı tanı konmasına neden olabileceği görüldü. Daha genişserilerde yapılacak araştırmalarda nihai boyların da değerlendirilmesi ile tanıkriterlerinin yeniden belirlenmesi gerektiği vurgulandı, In tro duc ti on: In this study, we aimed to investigate the factors that determine responseto growth hormone GH treatment in children with isolated idiopathic GH deficiencytreated in our university hospital. Materials and Methods: The data of 149 patients followed in our university hospital betweenJanuary 1995 and December 2005 were evaluated in patient charts retrospectively. Results: The maximum GH response to clonidine and glucagon stimulation tests was4.58 and 6.01 ng/ml respectively. The mean GH dose was 0.215 0.18-0.25 mg/kg/week.Height SDS significantly increased after the first and second years of GH treatment p< 0.05 . There was a negative correlation between the maximum response tostimulation tests and the response to GH treatment p< 0.05 . When the patients weregrouped according to the maximum response to stimuli as 7 ng/ml,the best response to therapy was observed in the group with the least response 0.05 .Conclusions: Patients who were started treatment at an early age, whose response to GH stimulation tests were lower, andwho were given higher doses benefited more from GH treatment. Therefore, we suggest that the diagnostic criteria for GHdeficiency must be reevaluated and the random cut-off of

Bu çalışmada, Uludağ Üniversitesi Tıp Fakültesi Pediatrik Endokrinoloji Bilim Dalımız'da büyüme hormonu (BH) eksikliği tanısıyla tedavi alan çocukların lineer büyümeleri, kilo artışı, kemik yaşı ilerleme durumu ve puberte ilerleme hızlarının değerlendirilmesi amaçlandı. Ocak 1995?Aralık 2005 tarihleri arasındaki veriler retrospektif olarak değerlendirildi.Toplam 230 hasta çalışmaya alındı. Hastalar Grup-1; İzole BHE, Grup-2; Turner sendromu ve Grup-3; Diğer olarak ayrıldı.Tanı aşamasında bakılan ortalama maksimum BH yanıtı klonidin stimülasyon testi için 4,58 ng/ml, glukagon stimülasyon testi için ise 6,01 ng/ml bulundu. Ortalama BH dozu 0,215 (0,15- 0,46) mg/kg/hafta olarak belirlendi. BH tedavisi ile her üç grupta da boy SDS anlamlı olarak arttı (p

Gi rifl: Kasım-Aralık 2009 tarihleri arasında influenza benzeri hastalık tanımına uyan vepnömoniyle gelişen, hastaneye yatırılan 68 olgu ile ilgili deneyimlerimizin paylaşılmasıamaçlandı.Gereç ve Yöntem: Kanıtlanmış pandemik 2009 influenza pozitif olgular ile negatifolgular klinik belirti ve bulgular, laboratuvar ve radyolojik görüntüleme sonuçları,hastanede ve yoğun bakımda yatış süreleri, almış oldukları tedaviler vekomplikasyonlar açısından karşılaştırıldı.Bulgular: Her iki grup arasında cinsiyet dağılımı açısından anlamlı bir fark saptanmadı.Pozitif olgularda 5 yaş üstü olgu sayısı aynı yaş grubundaki negatif olgulara göreanlamlı oranda yüksek saptandı p=0,004 . Pozitif olguların %78,8'inin, negatif olguların%68,8'inin altta yatan hastalığı vardı p=0,57 . Pozitif grupta ishal görülme oranı negatifgruptan anlamlı olarak yüksek saptandı p=0,02 . Mevsimsel influenza aşılanmaoranlarının düşüklüğü dikkat çekiciydi. Her iki grup arasında aşılanma oranlarıaçısından anlamlı bir fark saptanmadı p=0,99 .Sonuç: Hastalığın ciddiyeti pozitif ve negatif olgularda benzer seyretmiştir. Her ikigrupta da altta yatan hastalığı olanların oranının yükseldiği dikkat çekmektedir, In tro duc ti on: The aim of this study is to share our experience of sixty-eight pediatric hospitalizations associated with influenza-like illness and pneumonia betweenNovember, 2009 and December, 2009.Materials and Methods: Clinical signs and symptoms, laboratory and radiological results,length of stay in hospital and intensive care unit, treatments and complications werecompared in laboratory confirmed pandemic influenza A positive and negative cases.Results: There was no significant difference in gender distribution between the twogroups. The number of positive cases in patients over 5 years of age were significantlyhigher than the same age group in negative patients p=0.004 . There were underlyinghealth conditions in 78.8% of the positive cases and in 68.8% of the negative cases p=0.57 . The incidence of diarrhea in positive group was significantly higher than in thenegative group p=0.02 . Low immunization rates of the seasonal influenza vaccine wereremarkable in each group. There was no significant difference in vaccination ratesbetween the two groups p=0.99 .Conclusions: The severity of the disease remained similar in patients with positive andnegative groups. In both groups, the high ratio of those having an underlying disease wasnoteworthy

The frequency of bacterial factors causing central nervous system infections has decreased as a result of the development of our national immunization program. In this study, it is aimed to obtain the data of our local surveillance by defining the viral etiology in cases diagnosed with meningoencephalitis for 1 year. Previously healhty 186 children, who applied with findings suggesting viral meningoencephalitis to 8 different tertiary health centers between August 2018 and August 2019, in Istanbul, were included. The cerebrospinal fluid (CSF) sample was evaluated by polymerase chain reaction. The M:F ratio was 1.24 in the patient group, whose age ranged from 1 to 216 months (mean 40.2 +/- 48.7). Viral factor was detected in 26.8%. Enterovirus was the most common agent (24%) and followed by Adenovirus (22%) and HHV type 6 (22%). In the rest of the samples revealed HHV type 7 (10%), EBV (6%), CMV (6%), HSV type 1 (6%), Parvovirus (4%) and VZV (2%). The most common symptoms were fever (79%) and convulsions (45.7%). Antibiotherapy and antiviral therapy was started 48.6% and 4% respectively. Mortality and sequela rate resulted 0.53% and 3.7%, respectively. This highlights the importance of monitoring trends in encephalitis in Turkey with aview to improving pathogen diagnosis for encephalitis and rapidly identifying novel emerging encephalitis-causing pathogens that demand public health action especially in national immunisation programme. Turkish Pediatric Institution [04] This study was supported by the Turkish Pediatric Institution within the framework of the Initial R&D projects support program (02/14/2019 ID 04).

Objectives: the aim of this study is to identify the epidemiological, clinical, and laboratory features of coronavirus disease 2019 (COVID-19) in children.Methods: a retrospective study was conducted by pediatric infectious disease specialists from 32 different hospitals from all over Turkey by case record forms. Pediatric cases who were diagnosed as COVID-19 between March 16, 2020, and June 15, 2020 were included. Case characteristics including age, sex, dates of disease onset and diagnosis, family, and contact information were recorded. Clinical data, including the duration and severity of symptoms, were also collected. Laboratory parameters like biochemical tests and complete blood count, chest X-ray, and chest computed tomography (CT) were determined. Results: there were 1,156 confirmed pediatric COVID-19 cases. In total, male cases constituted 50.3% (n = 582) and females constituted 49.7% (n = 574). The median age of the confirmed cases was 10.75 years (4.5-14.6). Of the total cases, 90 were younger than 1 year of age (7.8%), 108 were 1-3 years of age (9.3%), 148 were 3-6 years of age (12.8%), 298 were 6-12 years of age (25.8%), 233 were 12-15 years of age (20.2%), and 268 cases were older than 15 years of age (23.2%). The most common symptom of the patients at the first visit was fever (50.4%) (n = 583) for a median of 2 days (IQR: 1-3 days). Fever was median at 38.4 degrees C (38.0-38.7 degrees C). The second most common symptom was cough (n = 543, 46.9%). The other common symptoms were sore throat (n = 143, 12.4%), myalgia (n = 141, 12.2%), dyspnea (n = 118, 10.2%), diarrhea (n = 112, 9.7%), stomachache (n = 71, 6.1%), and nasal discharge (n = 63, 5.4%). When patients were classified according to disease severity, 263 (22.7%) patients were asymptomatic, 668 (57.7%) patients had mild disease, 209 (18.1%) had moderate disease, and 16 (1.5%) cases had severe disease. One hundred and forty-nine (12.9%) cases had underlying diseases among the total cases; 56% of the patients who had severe disease had an underlying condition (p < 0.01). The need for hospitalization did not differ between patients who had an underlying condition and those who do not have (p = 0.38), but the need for intensive care was higher in patients who had an underlying condition (p < 0.01). Forty-seven (31.5%) of the cases having underlying conditions had asthma or lung disease (38 of them had asthma). Conclusions: to the best of our knowledge, this is one of the largest pediatric data about confirmed COVID-19 cases. Children from all ages appear to be susceptible to COVID-19, and there is a significant difference in symptomatology and laboratory findings by means of age distribution., NA